| | Name | Initial Conc. (uM) | Volume (fL) | Buffered |
| 1 | APC | 30 | 1000 | Yes |
| | arachodonylphosphatidylcholine is the favoured substrate from Wijkander and Sundler, JBC 202 pp 873-880, 1991. Their assay used 30 uM substrate, which is what the kinetics in this model are based on. For the later model we should locate a more realistic value for APC. For now it is treated as a buffered metabolite. |
| 2 | DAG-Ca-PLA2* | 0 | 1000 | No |
| | |
| 3 | PIP2-Ca-PLA2* | 0 | 1000 | No |
| | |
| 4 | PIP2-PLA2* | 0 | 1000 | No |
| | |
| 5 | PLA2* | 0 | 1000 | No |
| | Phosphorylated PLA2. The site differs from the site phosphorylated by PKC. See Nemenoff et al 1993 JBC 268(3):1960-1964 |
| 6 | PLA2*-Ca | 0 | 1000 | No |
| | Phosphorylated and active form of PLA2. Several kinases act on it: PKA: Wightman et al JBC 257 pp6650 1982 PKC: Many refs, eg Gronich et al JBC 263 pp 16645, 1988 but see Lin etal MAPK: Lin et al, Cell 72 pp 269, 1993. Show 3x with MAPK but not PKC alone The Nemenoff assays are conducted in rather high Ca so I have assumed a Ca binding step. |
| 7 | PLA2-Ca* | 0 | 1000 | No |
| | The generic Ca-activated form ofPLA2. Leslie and Channon 1990 BBA 1045:261. |
| 8 | PLA2-cytosolic | 0.4 | 1000 | No |
| | cPLA2 IV form has mol wt of 85 Kd. Glaser et al 1993 TIPS 14:92-98. Calculated cytosolic concentration is ~300 nM from Wijkander and Sundler 1991 Eur J Biochem 202:873 Leslie and Channon 1990 BBA 1045:261 use about 400 nM. Decent match. Use 400 nM. |
